Definium Therapeutics (DFTX) Liabilities and Shareholders Equity (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $401.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $401.3 million, up 45.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 15.27% YoY), and the FY2025 annual result was $440.1 million, up 45.66% from the prior year.
• Liabilities and Shareholders Equity fell to $401.3 million in Q1 2026 per DFTX's latest filing, from $440.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $440.1 million in Q4 2025 and troughed at $124.5 million in Q4 2023.
• A 5-year average of $234.3 million and a median of $236.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity fell 26.74% in 2023, then surged 142.61% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $170.0 million in 2022, then declined by 26.74% to $124.5 million in 2023, then jumped by 142.61% to $302.2 million in 2024, then soared by 45.66% to $440.1 million in 2025, then slipped by 8.82% to $401.3 million in 2026.
• Business Quant data shows DFTX's Liabilities and Shareholders Equity at $401.3 million in Q1 2026, $440.1 million in Q4 2025, and $236.9 million in Q3 2025.